ArticleJournal of neurovirology2026
Serum but not cerebrospinal fluid biomarkers are associated with domain-specific cognitive performance in PWH.
Article in Journal of neurovirology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBlood biomarkers would be the ideal tool in routine practice in early identifying People With HIV (PWH) with low cognitive performance (LNP). We aimed to assess the diagnostic performance of neurodegeneration and brain injury biomarkers in cerebrospinal fluid (CSF) and serum to detect global and domain-specific cognitive performance in PWH.
methodsRetrospective cross-sectional study. Serum and CSF Tau, NFL, GFAP, UCH-L1, BDNF, AB40 and AB42, and CSF SNAP25 concentrations were measured by Single Molecule Assay (SiMoA) in treated PWH without neurological confounders. Global Deficit Score (GDS) was calculated assessing 6 cognitive domains; LNP defined as GDS ≥ 0.5. Correlations, AUROC, and diagnostic accuracy metrics were used to study the relationships between GDS, domain impairment, and biomarkers.
results74 adult PWH on suppressive antiretroviral therapy were included (53% male, age 56 ± 9.8 years, median CD4 + T-cells 542/µL); 50% had LNP. Despite moderate-to-strong correlations between CSF and serum biomarkers, only serum GFAP was associated with LNP (AUROC 0.67, p = 0.007, sensitivity 67.6%, specificity 64.9%). Serum Tau was associated with impairment in memory (AUROC 0.66, p = 0.031, sensitivity 85.0%, specificity 42.9%), processing speed (AUROC 0.71, p = 0.002, sensitivity 46.0%, specificity 99.5%), and motor functions (AUROC 0.74, p < 0.001, sensitivity 55.6% specificity 88.5%); serum NFL with executive dysfunction (AUROC 0.66, p = 0.024, sensitivity 80.8%, specificity 50.0%). Variably combining serum GFAP, Tau, and NFL did not improve accuracy in detecting LNP.
conclusionsWe observed very selective relationships between specific serum biomarkers and cognitive phenotypes, suggesting heterogeneity of the mechanisms underlying LNP in PWH, which may limit the diagnostic power of biomarker-based strategies.
Indexed as
Identifiers
41772353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.